JP7883513B2 - ベンゾイソオキサゾール誘導体及びその使用 - Google Patents

ベンゾイソオキサゾール誘導体及びその使用

Info

Publication number
JP7883513B2
JP7883513B2 JP2023556473A JP2023556473A JP7883513B2 JP 7883513 B2 JP7883513 B2 JP 7883513B2 JP 2023556473 A JP2023556473 A JP 2023556473A JP 2023556473 A JP2023556473 A JP 2023556473A JP 7883513 B2 JP7883513 B2 JP 7883513B2
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
membered
substituted
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023556473A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509625A (ja
JP2024509625A5 (cg-RX-API-DMAC7.html
Inventor
ジョン ベックウィズ,ローハン,エリック
ボナッジ,サイモン
チェルニイェンコ,アルティオム
ストロカ コブ,ジェニファー
アリーシャ ダレス,ナタリー
デューハースト,ジャネッタ
ファザル,アリーム
ジェイムス ヘッセ,マシュー
ジェイン,ラマ
ライアン ケリガン,ジョン
マリク,ハスネイン,アーメド
マニング,ジェームス,アール.
オブライエン,ゲイリー
ダブリュ. パターソン,アンドリュー
マリエ-フランス トムセン,ノエル
ティング,パメラ,ワイエフ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2024509625A publication Critical patent/JP2024509625A/ja
Publication of JP2024509625A5 publication Critical patent/JP2024509625A5/ja
Application granted granted Critical
Publication of JP7883513B2 publication Critical patent/JP7883513B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023556473A 2021-03-15 2022-03-14 ベンゾイソオキサゾール誘導体及びその使用 Active JP7883513B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163161141P 2021-03-15 2021-03-15
US63/161,141 2021-03-15
US202163164125P 2021-03-22 2021-03-22
US63/164,125 2021-03-22
PCT/IB2022/000134 WO2022195355A1 (en) 2021-03-15 2022-03-14 Benzisoxazole derivatives and uses thereof

Publications (3)

Publication Number Publication Date
JP2024509625A JP2024509625A (ja) 2024-03-04
JP2024509625A5 JP2024509625A5 (cg-RX-API-DMAC7.html) 2025-03-24
JP7883513B2 true JP7883513B2 (ja) 2026-07-01

Family

ID=81579856

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023556473A Active JP7883513B2 (ja) 2021-03-15 2022-03-14 ベンゾイソオキサゾール誘導体及びその使用

Country Status (4)

Country Link
US (1) US20250276964A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308559A1 (cg-RX-API-DMAC7.html)
JP (1) JP7883513B2 (cg-RX-API-DMAC7.html)
WO (1) WO2022195355A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120129677A (zh) 2022-11-04 2025-06-10 百时美施贵宝公司 化合物及其用于治疗血红素病变的用途
WO2024255810A1 (en) * 2023-06-15 2024-12-19 Hangzhou Glubio Pharmaceutical Co., Ltd Dihydropyrimidine-2, 4 (1h, 3h) -dione-containing polycyclic derivatives and pharmaceutical composition thereof, preparation method thereof and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506922A (ja) 2017-01-31 2020-03-05 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
JP2022537605A (ja) 2019-09-12 2022-08-26 メッドシャイン ディスカバリー インコーポレイテッド Crbnタンパク質モジュレーターとしての二環式化合物
JP2024509981A (ja) 2021-03-15 2024-03-05 ノバルティス アーゲー ピラゾロピリジン誘導体及びその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
HUE033177T2 (en) 2012-01-17 2017-11-28 Astellas Pharma Inc Pyrazine carboxamide compound
CA3082579A1 (en) 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506922A (ja) 2017-01-31 2020-03-05 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
JP2022537605A (ja) 2019-09-12 2022-08-26 メッドシャイン ディスカバリー インコーポレイテッド Crbnタンパク質モジュレーターとしての二環式化合物
JP2024509981A (ja) 2021-03-15 2024-03-05 ノバルティス アーゲー ピラゾロピリジン誘導体及びその使用

Also Published As

Publication number Publication date
JP2024509625A (ja) 2024-03-04
WO2022195355A1 (en) 2022-09-22
EP4308559A1 (en) 2024-01-24
US20250276964A1 (en) 2025-09-04

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260310

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260619

R150 Certificate of patent or registration of utility model

Ref document number: 7883513

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150